Nambiar S - Search Results

1

Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports.

Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Kim PW, et al. Among authors: nambiar s. Drug Saf. 2012 Jun 1;35(6):447-57. doi: 10.2165/11597460-000000000-00000. Drug Saf. 2012. PMID: 22612850 Review.

2

Hypoglycemia in patients treated with linezolid.

Viswanathan P, Iarikov D, Wassel R, Davidson A, Nambiar S. Viswanathan P, et al. Among authors: nambiar s. Clin Infect Dis. 2014 Oct 15;59(8):e93-5. doi: 10.1093/cid/ciu487. Epub 2014 Jun 25. Clin Infect Dis. 2014. PMID: 24965346

3

Linezolid-associated peripheral and optic neuropathy in children.

Nambiar S, Rellosa N, Wassel RT, Borders-Hemphill V, Bradley JS. Nambiar S, et al. Pediatrics. 2011 Jun;127(6):e1528-32. doi: 10.1542/peds.2010-2125. Epub 2011 May 9. Pediatrics. 2011. PMID: 21555496

4

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.

Iarikov D, Wassel R, Farley J, Nambiar S. Iarikov D, et al. Among authors: nambiar s. Infect Dis Ther. 2015 Dec;4(4):433-58. doi: 10.1007/s40121-015-0092-8. Epub 2015 Oct 5. Infect Dis Ther. 2015. PMID: 26437630 Free PMC article.

5

Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.

Bradley JS, Wassel RT, Lee L, Nambiar S. Bradley JS, et al. Among authors: nambiar s. Pediatrics. 2009 Apr;123(4):e609-13. doi: 10.1542/peds.2008-3080. Epub 2009 Mar 16. Pediatrics. 2009. PMID: 19289450

6

Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.

Bart SM, Rubin D, Kim P, Farley JJ, Nambiar S. Bart SM, et al. Among authors: nambiar s. Clin Infect Dis. 2021 Aug 2;73(3):e602-e608. doi: 10.1093/cid/ciaa1712. Clin Infect Dis. 2021. PMID: 33173946

7

Meta-analysis of a possible signal of increased mortality associated with cefepime use.

Kim PW, Wu YT, Cooper C, Rochester G, Valappil T, Wang Y, Kornegay C, Nambiar S. Kim PW, et al. Among authors: nambiar s. Clin Infect Dis. 2010 Aug 15;51(4):381-9. doi: 10.1086/655131. Clin Infect Dis. 2010. PMID: 20624065

8

Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data.

Houstoun M, Reichman ME, Graham DJ, Nambiar S, Shamsuddin H, Jones SC, Cao K, Wernecke M, Lam C, Worrall CM, MaCurdy TE, Kelman JA. Houstoun M, et al. Among authors: nambiar s. Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):911-7. doi: 10.1002/pds.3644. Epub 2014 May 28. Pharmacoepidemiol Drug Saf. 2014. PMID: 24872151

9

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).

Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K, Goodwin A, Jang SH, Iarikov D, Farley J, Nambiar S. Naseer S, et al. Among authors: nambiar s. Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111. doi: 10.1093/cid/ciaa1799. Clin Infect Dis. 2021. PMID: 33393598 Clinical Trial.

10

Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials.

Bart SM, Nambiar S, Gopinath R, Rubin D, Farley JJ. Bart SM, et al. Among authors: nambiar s. Clin Infect Dis. 2021 Nov 2;73(9):e2607-e2612. doi: 10.1093/cid/ciaa860. Clin Infect Dis. 2021. PMID: 32584969

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page